Company intelligence / Profile preview
Akaal Pharma Pty Ltd
Melbourne, Victoria, Australiaakaalpharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed Phase 1 trials for AKP-11 showing safety, tolerability and efficacy in psoriasis and atopic dermatitis patients. Phase 2 clinical trial for AK-119 in atopic dermatitis was approved in May 2023 with patient dosing expected to begin in Q3 2023.
- Therapeutic areas
- NeurologyImmunologyDermatology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Akaal Pharma Pty Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akaal Pharma Pty Ltd.